Crystalvue Medical Corporation (6527) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Crystalvue Medical Corporation TWD 51.10, price TWD 75.00, upside -31.9%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Crystalvue Medical Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Crystalvue Medical Corporation manufactures and sells medical devices worldwide. The company offers optical coherence tomography, retinal cameras, tonometers, lens edgers, and gastroenterology supplies, as well as ODM/OEM services for automated nucleic acid extraction instrument and PCR system. It also sells minimal invasive endoscopic instrument supplies.
Show more
Crystalvue Medical Corporation manufactures and sells medical devices worldwide. The company offers optical coherence tomography, retinal cameras, tonometers, lens edgers, and gastroenterology supplies, as well as ODM/OEM services for automated nucleic acid extraction instrument and PCR system. It also sells minimal invasive endoscopic instrument supplies. The company was founded in 2009 and is based in Taoyuan City, Taiwan.
Stock analysis
Crystalvue Medical Corporation (6527) currently trades at 75.00 TWD, while our model-based Fair Value estimate is 51.10 TWD, implying the stock looks roughly 46.8% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 112.20 TWD per share, and 8 of the 16 models we run sit above the 75.00 TWD price.
Bear case: the Dividend Discount group reads lowest at 23.48 TWD, and 8 of the 16 models stay below the price. Evidence for this calculation is high.
Scenario range: 39.44 TWD (bear) to 68.90 TWD (bull), the price of 75.00 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Crystalvue Medical Corporation reported revenue of 949M TWD in FY2025 versus 722M TWD in FY2021, a compound +7.1%/yr. Reported net income was 147M TWD in FY2025, compounding +17.5%/yr from FY2021.
Key figures
Market cap 1.9B TWD (≈ $59.8M) · P/E ratio 13.0 · P/S ratio 2.02 · EPS (TTM) 5.76 TWD · Dividend yield 3.9% · Net margin 15.5% · Return on equity 15.0% · Return on assets (EBIT) 11.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 17% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −13% fair-value upside, at −32%, 6527 screens richer than that median.
Fair Value models
Bear 39.44 TWDFair Value 51.10 TWDBull 68.90 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (2.10 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+17.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+13.5%
Dividend (yield on the price)3.9%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 19%
Compare Crystalvue Medical Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 204 stocks
Beats the industry median on 10/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−32% · Below median
Profitability
Return on equity (TTM)15% · Top 25%
Return on assets8% · Top 25%
Net margin (TTM)17% · Top 25%
Operating margin (TTM)21% · Top 25%
Growth and dividend
Revenue growth−15% · Bottom 25%
Dividend yield (TTM)3.9% · Top 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (TTM)13.0× · Cheapest 25%
P/B1.85× · Cheaper than median
P/S (TTM)2.17× · Cheaper than median
EV/EBITDA10.3× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)0· sector 31
PAST (return on equity)60· sector 25
HEALTH (low debt)0· sector 96
DIVIDEND (yield)77· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Crystalvue Medical Corporation Fair Value". https://www.fairvalue-calculator.com/stock/6527
Frequently asked questions
Is Crystalvue Medical Corporation (6527) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 51.10 TWD versus a price of 75.00 TWD, about −32% upside (overvalued).
What is the fair value of 6527?
Our model-based fair value for Crystalvue Medical Corporation is 51.10 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 75.00 TWD.
What is the quality score of 6527?
Crystalvue Medical Corporation has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Crystalvue Medical Corporation (6527)?
Our model-based price target is the fair value of 51.10 TWD (as of Sep 24, 2026) from 16 valuation models. Cautious scenario 39.44 TWD, optimistic scenario 68.90 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Crystalvue Medical Corporation stock forecast for 2026?
Our models put fair value at 51.10 TWD, about −32% upside versus a price of 75.00 TWD (overvalued). Cautious scenario 39.44 TWD, optimistic scenario 68.90 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Crystalvue Medical Corporation (6527)?
Crystalvue Medical Corporation reported trailing-twelve-month revenue of about 874M TWD (latest available figure, as of Sep 24, 2026).
Does Crystalvue Medical Corporation pay a dividend?
Crystalvue Medical Corporation currently shows a dividend yield of about 3.87% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Crystalvue Medical Corporation (6527)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Crystalvue Medical Corporation it is 51.10 TWD per share (as of Sep 24, 2026), against a price of 75.00 TWD. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Crystalvue Medical Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6527 trades above its calculated fair value: price 75.00 TWD, fair value 51.10 TWD, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6527?
No. The price is what the market pays today (75.00 TWD); the fair value is what the company's own numbers justify (51.10 TWD). For Crystalvue Medical Corporation the two are 23.90 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Crystalvue Medical Corporation worth?
The market values Crystalvue Medical Corporation at about 1.9B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 75.00 TWD; our models calculate a fair value of 51.10 TWD per share.
What do the bullish and bearish scenarios say about 6527?
Our models span a range for Crystalvue Medical Corporation: cautious scenario 39.44 TWD, base 51.10 TWD, optimistic 68.90 TWD per share (as of Sep 24, 2026, price 75.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6527?
Crystalvue Medical Corporation trades at a price-to-earnings ratio of 13.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 51.10 TWD is built from several models across several years. Other multiples: P/B 1.9, P/S 2.2, EV/EBITDA 10.3.
How solid is the balance sheet of Crystalvue Medical Corporation (6527)?
Balance-sheet figures for Crystalvue Medical Corporation (as of Sep 24, 2026): return on equity 15.0%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 6527 from its 52-week high?
Crystalvue Medical Corporation trades at 75.00 TWD, about 10% below its 52-week high of 83.70 TWD and 17% above the low of 64.05 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 51.10 TWD is for.
Which stocks are comparable to Crystalvue Medical Corporation?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Crystalvue Medical Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price 75.00 TWD, calculated fair value 51.10 TWD (−32%), Quality Score 57/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6527 calculated?
We run Crystalvue Medical Corporation through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 51.10 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Crystalvue Medical Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Crystalvue Medical Corporation (6527)?
The closing price on Sep 24, 2026 was 75.00 TWD. Our model-based fair value is 51.10 TWD, about −32% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Crystalvue Medical Corporation right now?
The price sits above even our optimistic bull case (68.90 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Crystalvue Medical Corporation
How large is the market capitalisation of Crystalvue Medical Corporation (6527)?
The market capitalisation of Crystalvue Medical Corporation is 1.9B TWD (≈ $59.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Crystalvue Medical Corporation (6527)?
The price-to-sales ratio of Crystalvue Medical Corporation is 2.02 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Crystalvue Medical Corporation (6527)?
Earnings per share at Crystalvue Medical Corporation are 5.76 TWD (price ÷ EPS = P/E 13.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Crystalvue Medical Corporation (6527)?
The dividend yield of Crystalvue Medical Corporation is 3.9% (payout 50.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Crystalvue Medical Corporation (6527)?
The net margin of Crystalvue Medical Corporation is 15.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Crystalvue Medical Corporation (6527)?
The return on equity (ROE) of Crystalvue Medical Corporation is 15.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Crystalvue Medical Corporation (6527)?
On an EBIT basis the return on assets of Crystalvue Medical Corporation is 11.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Crystalvue Medical Corporation (6527)?
The operating margin of Crystalvue Medical Corporation is 21.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Crystalvue Medical Corporation (6527)?
Revenue at Crystalvue Medical Corporation is growing −15.1% versus a year earlier (3y avg +6.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Crystalvue Medical Corporation (6527)?
Earnings per share at Crystalvue Medical Corporation are growing +12.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Crystalvue Medical Corporation (6527) generate?
The free cash flow of Crystalvue Medical Corporation is −46.1M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Crystalvue Medical Corporation in the live analysis
One click puts Crystalvue Medical Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
